NCT04081779 2026-04-08
Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study
Fred Hutchinson Cancer Center
Phase NA Completed
Clinical Trials
1,398 trialsNCT04940468 2026-04-07
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
University of Colorado, Denver
Phase NA Completed
NCT04673617 2026-04-03
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Artiva Biotherapeutics, Inc.
Phase 1/2 Completed
NCT05763563 2026-03-31
Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT00428142 2026-03-27
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT02315612 2026-03-24
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01315132 2026-03-19
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
Thomas Jefferson University
Phase 2 Completed
NCT00006721 2026-03-16
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Completed
NCT07457112 2026-03-09
EHCancer
Zagazig University
Phase NA Completed
NCT03939026 2026-03-02
ALPHA
Allogene Therapeutics
Phase 1 Completed
NCT01712490 2026-02-27
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda
Phase 3 Completed
NCT02730299 2026-02-25
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd
Phase 3 Completed
NCT05371054 2026-02-23
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01203722 2026-02-19
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT03445858 2026-02-18
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Children's Hospital Medical Center, Cincinnati
Phase EARLY_PHASE1 Completed
NCT04214444 2026-02-12
EVAPOR
University Hospital, Tours
Phase 3 Completed
NCT02909777 2026-02-11
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03029338 2026-02-11
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Completed
NCT01625351 2026-02-06
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00875056 2026-01-30
MK-0683-103
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02704832 2026-01-30
PREPARE
Institut Bergonié
Phase NA Completed
NCT04593277 2026-01-23
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
Fred Hutchinson Cancer Center
Phase NA Completed
NCT00364286 2026-01-20
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05063591 2026-01-15
BRUOG-407
Brown University
Phase NA Completed
NCT02264613 2026-01-13
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Aileron Therapeutics, Inc.
Phase 1/2 Completed
NCT06558513 2026-01-12
To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors
Evopoint Biosciences Inc.
Phase 1/2 Completed
NCT02337829 2026-01-08
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
Phase 2 Completed
NCT02490891 2026-01-02
RGDLymphome
Centre Henri Becquerel
Phase 2 Completed
NCT04364256 2026-01-02
Muscle Stimulation for Physical Function During Stem Cell Transplant
VA Office of Research and Development
Phase NA Completed
NCT04022980 2025-12-30
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
Wake Forest University Health Sciences
Phase 1 Completed
NCT01695005 2025-12-26
A Study of LY3039478 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT04182204 2025-12-22
POLARGO
Hoffmann-La Roche
Phase 3 Completed
NCT05120570 2025-12-22
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Masonic Cancer Center, University of Minnesota
Phase 1/2 Completed
NCT01496976 2025-12-19
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03336138 2025-12-15
AMA
University Hospital, Toulouse
Phase NA Completed
NCT06004167 2025-12-09
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
Massachusetts General Hospital
Phase NA Completed
NCT05991973 2025-12-05
Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas
Zhejiang University
Phase 2 Completed
NCT02211755 2025-11-28
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02588651 2025-11-21
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03593187 2025-11-20
GENHIV
Assistance Publique - Hôpitaux de Paris
Phase 1/2 Completed
NCT02996773 2025-11-10
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
Phase 1 Completed
NCT03010176 2025-10-29
MK-1454-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT06439420 2025-10-01
CBT-I in PBT
Virginia Commonwealth University
Phase 2 Completed
NCT00690560 2025-09-30
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma
Centre Antoine Lacassagne
Phase 2 Completed
NCT02356159 2025-09-30
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT06389357 2025-09-29
web-based
Gazi University
Phase NA Completed
NCT01909934 2025-09-19
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Takeda
Phase 4 Completed
NCT02512497 2025-09-19
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT06063603 2025-09-18
ASCENT
Mayo Clinic
Phase NA Completed
NCT05267054 2025-09-15
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
BeiGene
Phase 1/2 Completed